clofibric acid has been researched along with Body Weight in 43 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 6.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| " The effect of etofibrate, the ethandiol-1,2 diester of nicotinic and clofibric acids on bile production was studied in male rats that received a daily dose of 300 mg of etofibrate/kg body weight by stomach tube for 10 days and were compared with control rats receiving the medium." | 3.69 | Effect of etofibrate on bile production in the normolipidemic rat. ( Bocos, C; Castro, M; Herrera, E; Orozco, E; Quack, G, 1995) |
| "To contribute to the understanding of the hypolipidemic action of etofibrate, which is the 1,2-ethandiol ester of clofibric acid and nicotinic acid, 300 mg of this drug/kg body weight or of the medium were administered daily by a stomach tube to normolipidemic rats." | 3.68 | Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis. ( Bocos, C; Castro, M; Herrera, E; Quack, G, 1993) |
| "Rainbow trout (Salmo gairdneri), average body weight of 450 g, were treated with 15, 25, or 35 mg/kg of ciprofibrate via intraperitoneal injection every other day for 2 to 3 weeks." | 3.68 | Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate. ( Baldwin, LA; Calabrese, EJ; Kostecki, PT; Yang, JH, 1990) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 2.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "Clofibric acid (CA) is an active metabolite of the blood lipid lowering agent clofibrate, a pharmaceutical designed to work as agonist of peroxisome proliferator-activated receptor alpha (PPARa)." | 1.42 | Chronic effects of clofibric acid in zebrafish (Danio rerio): a multigenerational study. ( André, A; Capitão, A; Carvalho, AP; Castro, LF; Coelho, I; Coimbra, AM; Gesto, M; Lacerda, R; Lima, D; Lyssimachou, A; Peixoto, MJ; Santos, MM; Soares, J, 2015) |
| "Ciprofibrate treatment also reduced 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity to a lesser extent but had no effect on 17-hydroxylase (17-OHase) activity." | 1.33 | Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat. ( Cooke, GM; Curran, IH; Hierlihy, AM; Karamanos, L; Mehta, R; Price, CA, 2006) |
| "Clofibric acid was an ineffective as clofibrate in producing effects (i." | 1.29 | Further studies on the involvement of selenium in peroxisome proliferation in rat liver. Comparison of effects with clofibric acid and perfluorooctanoic acid and the pharmacokinetics of [14C]clofibrate. ( Andersson, K; De Pierre, JW; Olsson, U; Sundberg, C, 1993) |
| "Ciprofibrate was fed to female Sprague-Dawley rats at concentrations of 0, 0." | 1.28 | Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats. ( Chow, CK; Glauert, HP; Srinivasan, SR, 1990) |
| "Nafenopin was also added to either a high carbohydrate (70% of kilocalories from glucose) or high fat (70% of kilocalories from lard) diet and fed to rats for either 1 or 3 weeks." | 1.27 | The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle. ( MacDonald, RS; Swan, PB, 1986) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Clofibrate was used as the standard product." | 1.26 | Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs. ( Bruseghini, L; Sanfeliu, C; Zapatero, J, 1981) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (32.56) | 18.7374 |
| 1990's | 19 (44.19) | 18.2507 |
| 2000's | 8 (18.60) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coimbra, AM | 1 |
| Peixoto, MJ | 1 |
| Coelho, I | 1 |
| Lacerda, R | 1 |
| Carvalho, AP | 1 |
| Gesto, M | 1 |
| Lyssimachou, A | 1 |
| Lima, D | 1 |
| Soares, J | 1 |
| André, A | 1 |
| Capitão, A | 1 |
| Castro, LF | 1 |
| Santos, MM | 1 |
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Owen, SF | 1 |
| Huggett, DB | 1 |
| Hutchinson, TH | 1 |
| Hetheridge, MJ | 1 |
| McCormack, P | 1 |
| Kinter, LB | 1 |
| Ericson, JF | 1 |
| Constantine, LA | 1 |
| Sumpter, JP | 1 |
| Atshaves, BP | 1 |
| Payne, HR | 1 |
| McIntosh, AL | 1 |
| Tichy, SE | 1 |
| Russell, D | 1 |
| Kier, AB | 1 |
| Schroeder, F | 1 |
| Sebestjen, M | 1 |
| Keber, I | 1 |
| Zegura, B | 1 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Hierlihy, AM | 1 |
| Cooke, GM | 1 |
| Curran, IH | 1 |
| Mehta, R | 1 |
| Karamanos, L | 1 |
| Price, CA | 1 |
| Calfee-Mason, KG | 1 |
| Lee, EY | 1 |
| Spear, BT | 1 |
| Glauert, HP | 3 |
| Calatayud, JM | 1 |
| Rao, MS | 2 |
| Lalwani, ND | 1 |
| Watanabe, TK | 1 |
| Reddy, JK | 1 |
| Lang, PD | 1 |
| Vollmar, J | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Vessby, B | 1 |
| Lithell, H | 1 |
| Hellsing, K | 1 |
| Ostlund-Lindqvist, AM | 1 |
| Gustafsson, IB | 1 |
| Boberg, J | 1 |
| Ledermann, H | 1 |
| Wirth, A | 1 |
| Middelhoff, G | 1 |
| Braeuning, C | 1 |
| Schlierf, G | 1 |
| Zapatero, J | 1 |
| Sanfeliu, C | 1 |
| Bruseghini, L | 1 |
| Stratmann, FW | 1 |
| Holler, HD | 1 |
| Hofmann, H | 1 |
| Schubotz, R | 1 |
| Schneider, J | 1 |
| Hausmann, L | 1 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Kaffarnik, H | 1 |
| Yamoto, T | 1 |
| Ohashi, Y | 1 |
| Teranishi, M | 1 |
| Takaoka, M | 1 |
| Manabe, S | 1 |
| Matsunuma, N | 1 |
| Makita, T | 1 |
| Espandiari, P | 1 |
| Thomas, VA | 1 |
| O'Brien, M | 1 |
| Noonan, D | 1 |
| Robertson, LW | 1 |
| Bocos, C | 2 |
| Orozco, E | 1 |
| Castro, M | 2 |
| Quack, G | 3 |
| Herrera, E | 2 |
| Olsson, U | 1 |
| Sundberg, C | 1 |
| Andersson, K | 1 |
| De Pierre, JW | 1 |
| Cattley, RC | 1 |
| Glover, SE | 1 |
| Barrass, NC | 1 |
| Price, RJ | 1 |
| Lake, BG | 1 |
| Orton, TC | 1 |
| Pacot, C | 1 |
| Charmoillaux, M | 1 |
| Goudonnet, H | 1 |
| Truchot, RC | 1 |
| Latruffe, N | 1 |
| Fincham, JE | 1 |
| Wülfroth, P | 1 |
| Benadé, AJ | 1 |
| Mikhailidis, DP | 1 |
| Ganotakis, ES | 1 |
| Spyropoulos, KA | 1 |
| Jagroop, IA | 1 |
| Byrne, DJ | 1 |
| Winder, AF | 1 |
| Morisseau, C | 1 |
| Derbel, M | 1 |
| Lane, TR | 1 |
| Stoutamire, D | 1 |
| Hammock, BD | 1 |
| Nicod, L | 1 |
| Rodriguez, S | 1 |
| Jacqueson, A | 1 |
| Viollon-Abadie, C | 1 |
| Berthelot, A | 1 |
| Richert, L | 1 |
| Aguilar-Salinas, CA | 1 |
| Fanghänel-Salmón, G | 1 |
| Meza, E | 1 |
| Montes, J | 1 |
| Gulías-Herrero, A | 1 |
| Sánchez, L | 1 |
| Monterrubio-Flores, EA | 1 |
| González-Valdez, H | 1 |
| Gómez Pérez, FJ | 1 |
| Yu, XX | 1 |
| Odle, J | 1 |
| Drackley, JK | 1 |
| Fischer, M | 1 |
| Falkensammer, C | 1 |
| Gustafson, A | 1 |
| Makowska, JM | 2 |
| Gibson, GG | 2 |
| Bonner, FW | 1 |
| Marsman, DS | 1 |
| Goldsworthy, TL | 1 |
| Popp, JA | 1 |
| Zhao, Y | 1 |
| Jaskiewicz, J | 1 |
| Harris, RA | 1 |
| Yeldandi, AV | 1 |
| Subbarao, V | 1 |
| Yang, JH | 1 |
| Kostecki, PT | 1 |
| Calabrese, EJ | 1 |
| Baldwin, LA | 1 |
| Srinivasan, SR | 1 |
| Chow, CK | 1 |
| Anders, C | 1 |
| Goldfarb, PS | 1 |
| Bonner, F | 1 |
| Esbenshade, TA | 1 |
| Kamanna, VS | 1 |
| Newman, HA | 1 |
| Tortorella, V | 1 |
| Witiak, DT | 1 |
| Feller, DR | 1 |
| Mohan, PF | 1 |
| Cleary, MP | 1 |
| Fournel, S | 1 |
| Magdalou, J | 1 |
| Pinon, P | 1 |
| Siest, G | 1 |
| MacDonald, RS | 1 |
| Swan, PB | 1 |
4 trials available for clofibric acid and Body Weight
| Article | Year |
|---|---|
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibr | 1982 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, | 2001 |
[New drug combination for medical management of hyperlipemia: clinical study].
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; | 1977 |
39 other studies available for clofibric acid and Body Weight
| Article | Year |
|---|---|
Chronic effects of clofibric acid in zebrafish (Danio rerio): a multigenerational study.
Topics: Animals; Body Weight; Clofibric Acid; Embryonic Development; Fertility; Gene Expression Regulation; | 2015 |
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid.
Topics: Animals; Anticholesteremic Agents; Body Composition; Body Weight; Clofibric Acid; Dose-Response Rela | 2010 |
Sexually dimorphic metabolism of branched-chain lipids in C57BL/6J mice.
Topics: Animals; Body Composition; Body Weight; Carrier Proteins; Clofibric Acid; Dietary Fats; Esterificati | 2004 |
Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat.
Topics: 17-Hydroxysteroid Dehydrogenases; Administration, Oral; Adrenal Glands; Animals; Body Weight; Choles | 2006 |
Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Blotting, Western; Body Weight; Cell Nucleus; Clofibric Acid; | 2008 |
Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
Topics: Aging; Animal Feed; Animals; Body Weight; Clofibrate; Clofibric Acid; Hypolipidemic Agents; Lipofusc | 1983 |
Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
Topics: Animals; Anisoles; Antioxidants; Body Weight; Butylated Hydroxyanisole; Carcinogens; Clofibrate; Clo | 1984 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Aci | 1983 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric | 1980 |
Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
Topics: Animals; Blood Cell Count; Body Weight; Clofibrate; Clofibric Acid; Dogs; Female; Male; Organ Size; | 1981 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric A | 1981 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
Age-related changes in the susceptibility to clofibric acid, a hypolipidemic agent, of male rat liver.
Topics: Administration, Oral; Aging; Animals; Body Weight; Cholesterol; Clofibric Acid; Cytochrome P-450 Enz | 1995 |
The herbicide dicamba (2-methoxy-3,6-dichlorobenzoic acid) is a peroxisome proliferator in rats.
Topics: Acyl-CoA Oxidase; Animals; Base Sequence; Body Weight; Clofibric Acid; Cytochrome P-450 CYP4A; Cytoc | 1995 |
Effect of etofibrate on bile production in the normolipidemic rat.
Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Clofibric Acid; Lipids; Male; Org | 1995 |
Further studies on the involvement of selenium in peroxisome proliferation in rat liver. Comparison of effects with clofibric acid and perfluorooctanoic acid and the pharmacokinetics of [14C]clofibrate.
Topics: Animals; Body Weight; Caprylates; Catalase; Clofibric Acid; Eating; Fatty Acids; Fluorocarbons; Live | 1993 |
Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to carcinogenesis and nuclear localization.
Topics: Animals; Body Weight; Carcinogens; Cell Nucleus; Clofibric Acid; Diethylhexyl Phthalate; DNA; Guanos | 1993 |
Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis.
Topics: Adipose Tissue; Animals; Body Weight; Clofibric Acid; Hypolipidemic Agents; Lipids; Lipolysis; Liver | 1993 |
Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver.
Topics: Animals; Body Weight; Bromodeoxyuridine; Cell Division; Clofenapate; Clofibric Acid; DNA; Hepatomega | 1993 |
Role of thyroid state on induction by ciprofibrate of laurate hydroxylase and peroxisomal enzymes in rat liver microsomes.
Topics: Animals; Body Weight; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Enzyme | 1993 |
Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Body Weight; Chlorocebus aethiops; Clofibric Acid; Coron | 1996 |
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hype | 1998 |
Differential induction of hepatic drug-metabolizing enzymes by fenvaleric acid in male rats.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Body Weight; Clofibric Acid; Cytochrome P-450 | 1999 |
Clofibric acid or diethylmaleate supplemented diet decrease blood pressure in DOCA-salt treated male Sprague Dawley rats--relation with liver antioxidant status.
Topics: Animals; Blood Pressure; Body Weight; Catalase; Clofibric Acid; Desoxycorticosterone; Diet; Glutathi | 2000 |
Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissues.
Topics: Acyl-CoA Oxidase; Animals; Animals, Newborn; Aspirin; Body Weight; Carnitine O-Palmitoyltransferase; | 2001 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoprote | 1979 |
Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation.
Topics: Animals; Body Weight; Callithrix; Clofibric Acid; Cricetinae; Cytochrome P-450 Enzyme System; Enzyme | 1992 |
Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
Topics: Animals; Body Weight; Carcinogenicity Tests; Cell Death; Cell Division; Clofibric Acid; DNA, Neoplas | 1992 |
Effects of clofibric acid on the activity and activity state of the hepatic branched-chain 2-oxo acid dehydrogenase complex.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Acyl-CoA Dehydrogenase; Animals; Blotting, Northe | 1992 |
Quantitative analysis of hepatocellular lesions induced by di(2-ethylhexyl)phthalate in F-344 rats.
Topics: Animals; Body Weight; Clofibric Acid; Diet; Diethylhexyl Phthalate; Fibric Acids; Liver Neoplasms, E | 1990 |
Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate.
Topics: Acyl-CoA Oxidase; Analysis of Variance; Animals; Blotting, Western; Body Weight; Catalase; Clofibrat | 1990 |
Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
Topics: Administration, Oral; Animals; Body Weight; Clofibrate; Clofibric Acid; DNA; Female; Fibric Acids; H | 1990 |
Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Topics: Administration, Oral; Animals; Body Weight; Cell Division; Clofibrate; Clofibric Acid; Cytochrome P- | 1990 |
In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships.
Topics: 2-Methyl-4-chlorophenoxyacetic Acid; Acyl-CoA Oxidase; Animals; Body Weight; Cell Division; Choleste | 1990 |
Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Clofibrate; Clofibric Acid; Dehydroepiandrosterone; Disease Mod | 1989 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-4 | 1987 |
The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
Topics: Animals; Body Weight; Catalase; Clofibrate; Clofibric Acid; Fibric Acids; Hypolipidemic Agents; Male | 1986 |